Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients

NodeGuardian · 2026-03-18T01:43:51+00:00

Bristol Myers Squibb reported positive interim results for izalontamab brengitecan, a breast cancer drug, meeting key survival endpoints. It received Breakthrough Therapy Designation, but BMY shares fell slightly amid a "Hold" rating from analysts.

NodeGuardian

2026-03-18 01:43:51

Abstract generation in progress

Bristol Myers Squibb announced positive interim results from a Phase 3 trial of its new breast cancer drug, izalontamab brengitecan (Iza-bren), which met dual primary endpoints of progression-free and overall survival in pre-treated triple-negative breast cancer patients. The drug has also received Breakthrough Therapy Designation from both the U.S. FDA and China’s NMPA. Despite this positive news, BMY shares were slightly down, while analysts hold a “Hold” rating with an average price target of $60.09.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.